MA49886A - Anticorps anti-par2 et leurs utilisations - Google Patents
Anticorps anti-par2 et leurs utilisationsInfo
- Publication number
- MA49886A MA49886A MA049886A MA49886A MA49886A MA 49886 A MA49886 A MA 49886A MA 049886 A MA049886 A MA 049886A MA 49886 A MA49886 A MA 49886A MA 49886 A MA49886 A MA 49886A
- Authority
- MA
- Morocco
- Prior art keywords
- par2 antibodies
- par2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49886A true MA49886A (fr) | 2020-06-24 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049886A MA49886A (fr) | 2017-03-16 | 2018-03-16 | Anticorps anti-par2 et leurs utilisations |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10836822B2 (fr) |
| EP (1) | EP3596125A1 (fr) |
| JP (2) | JP7222901B2 (fr) |
| KR (1) | KR20190129925A (fr) |
| CN (1) | CN110446720B (fr) |
| AU (2) | AU2018235031B2 (fr) |
| BR (1) | BR112019018752A2 (fr) |
| CA (1) | CA3055251A1 (fr) |
| CL (1) | CL2019002626A1 (fr) |
| CO (1) | CO2019010975A2 (fr) |
| CR (1) | CR20190417A (fr) |
| IL (1) | IL269134B1 (fr) |
| MA (1) | MA49886A (fr) |
| MX (1) | MX2019010802A (fr) |
| NZ (1) | NZ757915A (fr) |
| PH (1) | PH12019502087A1 (fr) |
| SG (1) | SG11201908056QA (fr) |
| TW (1) | TWI788332B (fr) |
| UA (1) | UA125757C2 (fr) |
| WO (1) | WO2018167322A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| BR112013021526B1 (pt) | 2011-02-25 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| JP6227191B1 (ja) | 2014-12-19 | 2017-11-08 | 中外製薬株式会社 | 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法 |
| LT3233921T (lt) | 2014-12-19 | 2021-12-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antikūnai ir panaudojimo būdai |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| EP3574010A4 (fr) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-sclérostine et procédés d'utilisation |
| WO2022040345A1 (fr) * | 2020-08-18 | 2022-02-24 | Cephalon, Inc. | Anticorps anti-par-2 et procédés d'utilisation associés |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US20070053911A1 (en) * | 2003-03-11 | 2007-03-08 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| WO2005103081A2 (fr) | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
| BRPI0517058A (pt) * | 2004-11-04 | 2008-09-30 | New England Medical Center Inc | agonistas e antagonistas do receptor acoplado à proteìna g e métodos de uso |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
| CA2722600C (fr) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anticorps anti-hepcidine et methodes d'utilisation associees |
| CA2733041A1 (fr) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effecteurs de l'activation par-2 et leur utilisation dans la modulation d'une inflammation |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| SA111320266B1 (ar) | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
| WO2014022540A1 (fr) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Protéines multivalentes de liaison à un antigène |
| CA2881679C (fr) * | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-pcsk9 ayant des caracteristiques de liaison dependantes du ph |
| CN106459192B (zh) * | 2014-06-30 | 2021-08-03 | 默克专利股份公司 | 具有pH依赖性抗原结合的抗TNFa抗体 |
-
2018
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/fr unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 EP EP18714185.8A patent/EP3596125A1/fr active Pending
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 IL IL269134A patent/IL269134B1/en unknown
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 CA CA3055251A patent/CA3055251A1/fr active Pending
- 2018-03-16 KR KR1020197030092A patent/KR20190129925A/ko not_active Application Discontinuation
- 2018-03-16 BR BR112019018752A patent/BR112019018752A2/pt unknown
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
-
2019
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983A1/en active Pending
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3055251A1 (fr) | 2018-09-20 |
| US20210061905A1 (en) | 2021-03-04 |
| JP7222901B2 (ja) | 2023-02-15 |
| WO2018167322A1 (fr) | 2018-09-20 |
| US20180305450A1 (en) | 2018-10-25 |
| US11591389B2 (en) | 2023-02-28 |
| TWI788332B (zh) | 2023-01-01 |
| JP2020509762A (ja) | 2020-04-02 |
| CL2019002626A1 (es) | 2019-12-06 |
| CN110446720B (zh) | 2023-09-12 |
| EP3596125A1 (fr) | 2020-01-22 |
| US20230242639A1 (en) | 2023-08-03 |
| IL269134A (en) | 2019-11-28 |
| CN110446720A (zh) | 2019-11-12 |
| CR20190417A (es) | 2019-12-06 |
| AU2018235031B2 (en) | 2021-08-12 |
| UA125757C2 (uk) | 2022-06-01 |
| MX2019010802A (es) | 2019-10-30 |
| BR112019018752A2 (pt) | 2020-05-05 |
| IL269134B1 (en) | 2024-03-01 |
| AU2021257983A1 (en) | 2021-11-25 |
| AU2018235031A1 (en) | 2019-10-31 |
| NZ757915A (en) | 2023-05-26 |
| CO2019010975A2 (es) | 2019-10-21 |
| PH12019502087A1 (en) | 2020-03-09 |
| KR20190129925A (ko) | 2019-11-20 |
| US10836822B2 (en) | 2020-11-17 |
| TW201843176A (zh) | 2018-12-16 |
| SG11201908056QA (en) | 2019-09-27 |
| JP2023055895A (ja) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
| MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
| MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
| MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
| MA45690A (fr) | Anticorps anti-tgfb, méthodes et utilisations | |
| MA46036A (fr) | Anticorps anti-vegf-a et anti-ang2 et leurs utilisations | |
| MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques | |
| MA45543A (fr) | Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées |